ASX:RHT
ASX announcements, news coverage, and upcoming catalysts. Updated every Monday morning.
Resonance expects to release data from the DEVIMLA extended proof-of-concept trial for its non-invasive MRI liver fibrosis device. Patient recruitment completed July 2026. No specific date has been announced — based on the company's own guidance of ~1 month post-recruitment, data is expected imminently. Positive results could trigger an FDA 510(k) submission and unlock a $50M+ addressable market in MASH/MASLD diagnosis.
Cashflow update for the September quarter. First quarterly report to capture any early IAG alliance pipeline activity. Watch for commentary on EPoC data timing and any new CRO contract wins.
First half FY27 financials covering Jul-Dec 2026. First results period to show meaningful IAG alliance contribution (if any). Watch for revenue vs guidance range ($17-22M annualised), margin trends, and EPoC commercialisation update.
Full-year FY27 results. Management guided A$17-22M revenue and A$2.6-3.6M EBITDA. Watch for margin expansion as Bridge platform scales, IAG alliance revenue contribution, and any EPoC 510(k) submission or clearance news.
Resonance Health Limited (ASX:RHT) - Shares, Dividends & News - Intelligent Investor
Clinical Trial Imaging Partnership: IAG & Resonance Health
Image Analysis Group (IAG) and Resonance Health Announce Global Strategic Partnership in Clinical Trial Imaging
CEO Interview — Andrew Harrison discusses the IAG alliance and GLP-1 opportunity
Resonance Health Partners with UK CRO to Include SaMD Services in Global Clinical Trials
Resonance Health Executes Strategic Alliance and MSA with Image Analysis Group
Daily Special — Resonance Health, AML3D, Lion Energy, Latrobe Magnesium, Marquee Resources
Resonance Health Executes Global Alliance with Image Analysis Group
RHT signs a strategic alliance and master services agreement with London-headquartered Image Analysis Group (IAG), a global imaging CRO supporting 700+ clinical trials since 2007. FerriScan, HepaFatScan and LiverSmart become orderable within IAG's global trial proposals targeting obesity, MASH/MASLD, iron overload, hepatology and oncology.
ASX Announcement →Resonance Health: a profitable, self-funded platform priced as if the pipeline doesn't exist
The full report on the FY26 result: what the existing business is worth on standard multiples, where the fibrosis device sits against the competition, and what to watch. Priced at A$0.060 on the results day; the live figure shows where the shares are against that.
Resonance Health (ASX:RHT): Inside the FY26 Results and Outlook
Resonance Health Returns to Profit as SaMD Pipeline and Clinical Demand Open New Growth Paths
Resonance Health Posts Strong FY26 Growth as Earnings and Cash Generation Accelerate
Record revenue of A$15.8M, up 42% on FY25. Net profit of A$1.5M (vs A$1.7M loss in FY25). Normalised EBITDA up 83% to A$2.6M. Positive operating cash flow in every quarter. Net cash A$2.3M. FY27 guidance: revenue A$17-22M, EBITDA A$2.6-3.6M. EPoC fibrosis device trial fully enrolled with data analysis underway.
ASX Announcement →Can Resonance Health (ASX:RHT) Sustain Its Growth as AI Healthcare Expansion Continues?
Resonance Health Improves Cash Position as Clinical Trial Pipeline Expands
Q4 FY26 cashflow and activities update. Resonance Clinical's major pharma trial hit 60-patient recruitment target in April. TrialsWest Osborne Park clinic consistently profitable. Bridge automation platform reducing per-scan analysis time. Net cash positive for fourth consecutive quarter.
ASX Announcement →Update on EPoC fibrosis device DEVIMLA trial progress. Patient recruitment ongoing across trial sites. Webinar covering FY26 business portfolio including SaMD, Resonance Clinical, and TrialsWest divisions. First look at full-year revenue trajectory ahead of August results.
ASX Announcement →RHT upgrades underlying EBITDA guidance for FY26, citing stronger-than-expected performance across all three divisions. Revenue growth trajectory tracking ahead of initial guidance. First guidance upgrade since the company returned to profitability.
ASX Announcement →Q3 FY26 cashflow and activities. Third consecutive quarter of positive operating cash flow. A$13.8M major pharma trial recruitment on track. TrialsWest Mandurah clinic approaching breakeven. Forward order and tendered pipeline above A$12M for SaMD division.
ASX Announcement →RHT receives R&D tax incentive refund, bolstering cash position. Refund reflects significant ongoing investment in the EPoC liver fibrosis device and Bridge automation platform. Adds to the company's self-funded balance sheet.
ASX Announcement →H1 FY26 revenue up strongly on prior period. Resonance Clinical division winning major new contracts. TrialsWest expansion underway. EPoC device progressing through DEVIMLA validation study. Company on track to achieve first full-year profitability in FY26.
ASX Announcement →Q2 FY26 cashflow update. Second consecutive quarter of positive operating cash flow. Major pharma trial contract progressing well. SaMD pipeline growing. TrialsWest Mandurah clinic opened. Company reaffirms FY26 guidance.
ASX Announcement →Resonance Health (ASX:RHT): A Potential Game-Changer in Diagnosing Liver Fibrosis
Annual General Meeting presentation covering FY25 results, strategic priorities for FY26, and progress on the EPoC liver fibrosis device. Management outlined the three-division strategy (SaMD, Resonance Clinical, TrialsWest) and the pathway to sustained profitability.
ASX Announcement →Q1 FY26 cashflow and activities. First quarter of positive operating cash flow under FY26 guidance. New contracts signed for Resonance Clinical. SaMD division tracking to guidance. EPoC device validation study enrolling patients.
ASX Announcement →RHT hosts investor strategy day outlining the three-division growth roadmap. CEO Andrew Harrison presented detailed market opportunity analysis for FerriScan, HepaFatScan, and the EPoC fibrosis device. GLP-1 obesity trial market identified as a major growth vector. First detailed public framing of the TAM expansion thesis.
ASX Announcement →Long-serving chair announces retirement. New chair appointment process underway. Board refresh part of broader governance improvement programme following the return to profitability under CEO Harrison's leadership.
ASX Announcement →FY25 results: revenue A$11.1M, up 28%. Normalised EBITDA of −A$0.7M as reported (later restated to +A$1.4M in the FY26 comparatives after an unearned-income adjustment). Net loss A$1.7M. Company issues maiden FY26 guidance: revenue A$14-17M, positive EBITDA. Sets the stage for what would become the FY26 breakout year.
ASX Announcement →Q4 FY25 cashflow update. Resonance Clinical division growing strongly with new pharma client wins. SaMD pipeline at record levels. TrialsWest Osborne Park clinic delivering consistent revenue. Full-year FY25 results to follow in August.
ASX Announcement →